🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

112 results for “alcohol” Clear

  1. Arbaclofen Placarbil

    Indivior Europe Limited

    Alcohol Use Disorder

    phase 2 small molecule completed

    1 trial

  2. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial

  3. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  4. CMND-100

    Clearmind Medicine

    Alcohol Use Disorder

    phase 2 small molecule active

    1 trial

  5. CRV431 75mg

    Hepion Pharmaceuticals

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  6. CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

    phase 2 small molecule active

    1 trial

  7. Cannabidiol Placebo Capsules, Cannabidiol Capsules

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Alcohol dependence

    phase 2 small molecule active

    1 trial

  8. Comparator: MK0594 5 mg/day

    VYNE Therapeutics

    Alcohol Dependence

    phase 2 small molecule terminated

    1 trial

  9. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    1 trial

  10. EDP-305 1.5 mg

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  11. EDP-305 Dose 1

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  12. Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc, Fipaxalparant

    Elan Pharma International

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  13. Fipaxalparant, Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc

    Elan Pharma International

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  14. GIP/GLP-1a

    United Therapeutics Europe Ltd

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  15. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  16. HEC96719

    Sunshine Biopharma

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  17. ION224

    IONIS PHARMACEUTICALS INC

    Steatohepatitis, Nonalcoholic

    phase 2 small molecule completed

    1 trial

  18. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  19. MI-CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Abuse

    phase 2 other completed

    1 trial

  20. MI/CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholic, Marijuana Misuse

    phase 2 other completed

    1 trial

  21. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  22. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  23. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    3 trials

  24. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources